Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alpheus Announces Positive Glioma Treatment Phase 1/2 Results
Details : Low-Intensity Diffuse Ultrasound with the sensitizing agent, oral 5-aminolevulinic acid (5-ALA) is being investigated in patients with recurrent or refractory high-grade gliomas.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2024
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable